3-(3-fluoropropoxy)benzoic acid | 1227184-46-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(3-fluoropropoxy)benzoic acid
• CAS: 1227184-46-4
• 化学式: C₁₀H₁₁FO₃
• 分子量: 198.194
• InChiKey: XHUWPJNZLQVIGX-UHFFFAOYSA-N

物化性质

• 沸点：
  341.0±22.0 °C(Predicted)
• 密度：
  1.205±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(3-fluoropropoxy)benzoic acid 在 草酰氯 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 3-(3-fluoropropoxy)benzoyl chloride
  参考文献：
  名称：

  NEW COMPOUNDS 575

  摘要：

  本发明涉及式（I）的新化合物及其药物组成。此外，本发明涉及治疗方法，用于治疗和/或预防与Aβ相关的病理，如唐氏综合症、β-淀粉样蛋白血管病变，如但不限于脑淀粉样蛋白血管病变或遗传性脑出血，与认知受损相关的疾病，如但不限于MCI（轻度认知障碍）、阿尔茨海默病、记忆丧失、与阿尔茨海默病相关的注意力缺陷症状，与阿尔茨海默病或痴呆症等疾病相关的神经退行性疾病，包括血管性和退行性起源的混合性痴呆、早老性痴呆、老年痴呆和与帕金森病、进行性上核性麻痹或皮层基底节变性相关的痴呆。

  公开号：

  US20100125087A1
• 作为产物：
  描述：

  3-(3-fluoro-propoxy)-benzoic acid methyl ester 在 甲醇 、 sodium hydroxide 作用下， 反应 15.0h， 以39%的产率得到3-(3-fluoropropoxy)benzoic acid
  参考文献：
  名称：

  [EN] KETONE INHIBITORS OF LYSINE GINGIPAIN
  [FR] INHIBITEURS CÉTONE DE LYSINE GINGIPAÏNE

  摘要：

  本发明提供了如下式（I）所述的化合物，以及它们用于抑制牙龈假单胞菌（Porphyromonas gingivalis）的赖氨酸基因底物蛋白酶（Kgp）的用途。还描述了牙龈蛋白酶活性探针化合物和测定牙龈蛋白酶活性的方法，以及用于治疗与牙龈假单胞菌感染相关的疾病的方法，包括阿尔茨海默病等脑部疾病。

  公开号：

  WO2018053353A1

文献信息

• Ketone inhibitors of lysine gingipain
  申请人：CORTEXYME, INC.

  公开号：US10730826B2

  公开（公告）日：2020-08-04

  The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.

  本发明提供了根据本文所述式 I 的化合物及其用于抑制牙龈卟啉单胞菌的赖氨酸gingipain蛋白酶（Kgp）的用途。本发明还描述了龈肽酶活性探针化合物和检测龈肽酶活性的方法，以及治疗与牙龈卟啉单胞菌感染有关的疾病（包括阿尔茨海默病等脑部疾病）的方法。
• KETONE INHIBITORS OF LYSINE GINGIPAIN
  申请人：CORTEXYME, INC.

  公开号：US20190210960A1

  公开（公告）日：2019-07-11

  The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis . Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.
• [EN] NEW COMPOUNDS 575<br/>[FR] NOUVEAUX COMPOSÉS 575
  申请人：ASTRAZENECA AB

  公开号：WO2010056195A1

  公开（公告）日：2010-05-20

  The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Downs syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.